Depletion of phagocytic myeloid cells triggers spontaneous T cell- and NK cell-dependent antitumor activity

OncoImmunology

Volumn 1, Issue 8, 2012, Pages 1248-1257

  Guth, Amanda M ^a   Hafeman, Scott D ^a   Dow, Steven W ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Cancer; Cytokines; Innate immunity; Liposomal clodronate; Macrophages

Indexed keywords

CLODRONIC ACID; GAMMA INTERFERON; INTERLEUKIN 17;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL POPULATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; FIBROSARCOMA; GROWTH INHIBITION; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MOUSE; NATURAL KILLER CELL; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; T CELL DEPLETION; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH;

EID: 84874368497     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21317     Document Type: Article

References (64)

1. van Rooijen N, Kors N, Kraal G. Macrophage subset repopulation in the spleen: differential kinetics after liposome-mediated elimination. J Leukoc Biol 1989; 45:97-104; PMID:2521666.
2. Mathes M, Jordan M, Dow S. Evaluation of liposomal clodronate in experimental spontaneous autoimmune hemolytic anemia in dogs. Exp Hematol 2006; 34:1393-402; PMID:16982332; http://dx.doi.org/10.1016/j.exphem.2006.05.014.
3. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 1994; 174:83-93; PMID:8083541; http://dx.doi.org/10.1016/0022-1759(94)90012-4.
4. van Rooijen N, van Nieuwmegen R. Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate. An enzyme-histochemical study. Cell Tissue Res 1984; 238:355-8; PMID:6239690.
5. Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjällman AH, Ballmer-Hofer K, Schwendener RA. Clodronate-liposome-mediated depletion of tumourassociated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer 2006; 95:272-81; PMID:16832418; http://dx.doi.org/10.1038/sj.bjc.6603240.
6. Hafeman S, London C, Elmslie R, Dow S. Evaluation of liposomal clodronate for treatment of malignant histiocytosis in dogs. Cancer Immunol Immunother 2010; 59:441-52; PMID:19760220; http://dx.doi.org/10.1007/s00262-009-0763-y.
7. Gazzaniga S, Bravo AI, Guglielmotti A, van Rooijen N, Maschi F, Vecchi A, et al. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol 2007; 127:2031-41; PMID:17460736; http://dx.doi.org/10.1038/sj.jid.5700827.
8. Miselis NR, Wu ZJ, Van Rooijen N, Kane AB. Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol Cancer Ther 2008; 7:788-99; PMID:18375821; http://dx.doi.org/10.1158/1535-7163.MCT-07-0579.
9. Halin S, Rudolfsson SH, Van Rooijen N, Bergh A. Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model. Neoplasia 2009; 11:177-86; PMID:19177202.
10. Hiraoka K, Zenmyo M, Watari K, Iguchi H, Fotovati A, Kimura YN, et al. Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Sci 2008; 99:1595-602; PMID:18754872; http://dx.doi.org/10.1111/j.1349-7006.2008.00880.x.
11. Lepique AP, Daghastanli KR, Cuccovia IM, Villa LL. HPV16 tumor associated macrophages suppress antitumor T cell responses. Clin Cancer Res 2009; 15:4391-400; PMID:19549768; http://dx.doi.org/10.1158/1078-0432.CCR-09-0489.
12. Oosterling SJ, van der Bij GJ, Meijer GA, Tuk CW, van Garderen E, van Rooijen N, et al. Macrophages direct tumour histology and clinical outcome in a colon cancer model. J Pathol 2005; 207:147-55; PMID:16104052; http://dx.doi.org/10.1002/path.1830.
13. Robinson-Smith TM, Isaacsohn I, Mercer CA, Zhou M, Van Rooijen N, Husseinzadeh N, et al. Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res 2007; 67:5708-16; PMID:17575137; http://dx.doi.org/10.1158/0008-5472.CAN-06-4375.
14. Zhang W, Zhu XD, Sun HC, Xiong YQ, Zhuang PY, Xu HX, et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res 2010; 16:3420-30; PMID:20570927; http://dx.doi.org/10.1158/1078-0432.CCR-09-2904.
15. Piña Y, Boutrid H, Murray TG, Jager MJ, Cebulla CM, Schefler A, et al. Impact of tumor-associated macrophages in LH(BETA)T(AG) mice on retinal tumor progression: relation to macrophage subtype. Invest Ophthalmol Vis Sci 2010; 51:2671-7; PMID:20053982; http://dx.doi.org/10.1167/iovs.09-4255.
16. Ly LV, Baghat A, Versluis M, Jordanova ES, Luyten GP, van Rooijen N, et al. In aged mice, outgrowth of intraocular melanoma depends on proangiogenic M2-type macrophages. J Immunol 2010; 185:3481-8; PMID:20713886; http://dx.doi.org/10.4049/jimmunol.0903479.
17. Takahashi T, Ibata M, Yu Z, Shikama Y, Endo Y, Miyauchi Y, et al. Rejection of intradermally injected syngeneic tumor cells from mice by specific elimination of tumor-associated macrophages with liposomeencapsulated dichloromethylene diphosphonate, followed by induction of CD11b(+)/CCR3(-)/Gr-1(-) cells cytotoxic against the tumor cells. Cancer Immunol Immunother 2009; 58:2011-23; PMID:19365632; http://dx.doi.org/10.1007/s00262-009-0708-5.
18. Boonman ZF, Schurmans LR, van Rooijen N, Melief CJ, Toes RE, Jager MJ. Macrophages are vital in spontaneous intraocular tumor eradication. Invest Ophthalmol Vis Sci 2006; 47:2959-65; PMID:16799039; http://dx.doi.org/10.1167/iovs.05-1427.
19. Lee C-C. Liu, Ko-Jiunn Liu, Huang, Tze-Sing. Tumor-Associated Macrophage: Its Role in Tumor Angiogenesis. Journal of Cancer Molecules 2006; 2:135-40.
20. Nakao S, Kuwano T, Tsutsumi-Miyahara C, Ueda S, Kimura YN, Hamano S, et al. Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 betainduced neovascularization and tumor growth. J Clin Invest 2005; 115:2979-91 PMID:16239969; http://dx.doi.org/10.1172/JCI23298.
21. Kimura YN, Watari K, Fotovati A, Hosoi F, Yasumoto K, Izumi H, et al. Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis. Cancer Sci 2007; 98:2009-18; PMID:17924976; http://dx.doi.org/10.1111/j.1349-7006.2007.00633.x.
22. Sunderkötter C, Nikolic T, Dillon MJ, Van Rooijen N, Stehling M, Drevets DA, et al. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol 2004; 172:4410-7; PMID:15034056.
23. Jordan MB, van Rooijen N, Izui S, Kappler J, Marrack P. Liposomal clodronate as a novel agent for treating autoimmune hemolytic anemia in a mouse model. Blood 2003; 101:594-601; PMID:12393630; http://dx.doi.org/10.1182/blood-2001-11-0061.
24. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006; 16:53-65; PMID:16168663; http://dx.doi.org/10.1016/j.semcancer.2005.07.005.
25. Nagaraj S, Gabrilovich DI. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 2008; 68:2561-3; PMID:18413722; http://dx.doi.org/10.1158/0008-5472.CAN-07-6229.
26. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009; 58:49-59; PMID:18446337; http://dx.doi.org/10.1007/s00262-008-0523-4.
27. Frey AB. Myeloid suppressor cells regulate the adaptive immune response to cancer. J Clin Invest 2006; 116:2587-90; PMID:17016554; http://dx.doi.org/10.1172/JCI29906.
28. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006; 116:2777-90; PMID:17016559; http://dx.doi.org/10.1172/JCI28828.
29. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006; 66:1123-31; PMID:16424049; http://dx.doi.org/10.1158/0008-5472.CAN-05-1299.
30. Mazzoni A, Bronte V, Visintin A, Spitzer JH, Apolloni E, Serafini P, et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol 2002; 168:689-95; PMID:11777962.
31. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11:6713-21; PMID:16166452; http://dx.doi.org/10.1158/1078-0432.CCR-05-0883.
32. Li H, Han Y, Guo Q, Zhang M, Cao X. Cancerexpanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol 2009; 182:240-9; PMID:19109155.
33. Ilkovitch D, Lopez DM. The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res 2009; 69:5514-21; PMID:19549903; http://dx.doi.org/10.1158/0008-5472.CAN-08-4625.
34. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001; 166:678-89; PMID:11123353.
35. Watanabe S, Deguchi K, Zheng R, Tamai H, Wang LX, Cohen PA, et al. Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumordraining lymph nodes. J Immunol 2008; 181:3291-300; PMID:18714001.
36. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008; 13:23-35; PMID:18167337; http://dx.doi.org/10.1016/j.ccr.2007.12.004.
37. Ye XZ, Yu SC, Bian XW. Contribution of myeloidderived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis. J Genet Genomics 2010; 37:423-30; PMID:20659706; http://dx.doi.org/10.1016/S1673-8527(09)60061-8.
38. Fujimura T, Mahnke K, Enk AH. Myeloid derived suppressor cells and their role in tolerance induction in cancer. J Dermatol Sci 2010; 59:1-6; PMID:20570112; http://dx.doi.org/10.1016/j.jdermsci.2010.05.001.
39. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008; 222:162-79; PMID:18364001; http://dx.doi.org/10.1111/j.1600-065X.2008.00602.x.
40. Huitinga I, van Rooijen N, de Groot CJ, Uitdehaag BM, Dijkstra CD. Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J Exp Med 1990; 172:1025-33; PMID:2145387; http://dx.doi.org/10.1084/jem.172.4.1025.
41. Andrews DM, Smyth MJ. A potential role for RAG-1 in NK cell development revealed by analysis of NK cells during ontogeny. Immunol Cell Biol 2010; 88:107-16; PMID:19949422; http://dx.doi.org/10.1038/icb.2009.94.
42. Kasai M, Yoneda T, Habu S, Maruyama Y, Okumura K, Tokunaga T. In vivo effect of anti-asialo GM1 antibody on natural killer activity. Nature 1981; 291:334-5; PMID:7231554; http://dx.doi.org/10.1038/291334a0.
43. Fujii Y, Sendo F, Kamiyama T, Naiki M. IgG antibodies to asialoGM1 are more sensitive than IgM antibodies to kill in vivo natural killer cells and prematured cytotoxic T lymphocytes of mouse spleen. Microbiol Immunol 1990; 34:533-42; PMID:2170825.
44. Liu Z, Kim JH, Falo LD Jr., You Z. Tumor regulatory T cells potently abrogate antitumor immunity. J Immunol 2009; 182:6160-7; PMID:19414769; http://dx.doi.org/10.4049/jimmunol.0802664.
45. Lundqvist A, Yokoyama H, Smith A, Berg M, Childs R. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood 2009; 113:6120-7; PMID:19202127; http://dx.doi.org/10.1182/blood-2008-11-190421.
46. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009; 206:1717-25; PMID:19581407; http://dx.doi.org/10.1084/jem.20082492.
47. Jedema I, van der Werff NM, Barge RM, Willemze R, Falkenburg JH. New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood 2004; 103:2677-82; PMID:14630824; http://dx.doi.org/10.1182/blood-2003-06-2070.
48. Kamstock D, Guth A, Elmslie R, Kurzman I, Liggitt D, Coro L, et al. Liposome-DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma. Cancer Gene Ther 2006; 13:306-17; PMID:16138118; http://dx.doi.org/10.1038/sj.cgt.7700895.
49. Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol 2009; 183:937-44; PMID:19553533; http://dx.doi.org/10.4049/jimmunol.0804253.
50. Nagaraj S, Schrum AG, Cho HI, Celis E, Gabrilovich DI. Mechanism of T cell tolerance induced by myeloidderived suppressor cells. J Immunol 2010; 184:3106-16; PMID:20142361; http://dx.doi.org/10.4049/jimmunol.0902661.
51. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 2010; 70:68-77; PMID:20028852; http://dx.doi.org/10.1158/0008-5472.CAN-09-2587.
52. Tacke F, Ginhoux F, Jakubzick C, van Rooijen N, Merad M, Randolph GJ. Immature monocytes acquire antigens from other cells in the bone marrow and present them to T cells after maturing in the periphery. J Exp Med 2006; 203:583-97; PMID:16492803; http://dx.doi.org/10.1084/jem.20052119.
53. Tacke F, Randolph GJ. Migratory fate and differentiation of blood monocyte subsets. Immunobiology 2006; 211:609-18; PMID:16920499; http://dx.doi.org/10.1016/j.imbio.2006.05.025.
54. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, et al. HIF-1a regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 2010; 207:2439-53; PMID:20876310; http://dx.doi.org/10.1084/jem.20100587.
55. Choi JY, Oughton JA, Kerkvliet NI. Functional alterations in CD11b(+)Gr-1(+) cells in mice injected with allogeneic tumor cells and treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Int Immunopharmacol 2003; 3:553-70; PMID:12689660; http://dx.doi.org/10.1016/S1567-5769(03)00046-8.
56. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006; 203:2691-702; PMID:17101732; http://dx.doi.org/10.1084/jem.20061104.
57. Haile LA, Gamrekelashvili J, Manns MP, Korangy F, Greten TF. CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice. J Immunol 2010; 185:203-10; PMID:20525890; http://dx.doi.org/10.4049/jimmunol.0903573.
58. Augier S, Ciucci T, Luci C, Carle GF, Blin-Wakkach C, Wakkach A. Inflammatory blood monocytes contribute to tumor development and represent a privileged target to improve host immunosurveillance. J Immunol 2010; 185:7165-73; PMID:21078911; http://dx.doi.org/10.4049/jimmunol.0902583.
59. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008; 112:362-73; PMID:18354038; http://dx.doi.org/10.1182/blood-2007-11-120998.
60. Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Sautès-Fridman C, et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002; 99:2114-21; PMID:11877287; http://dx.doi.org/10.1182/blood.V99.6.2114.
61. Routes JM, Ryan S, Morris K, Takaki R, Cerwenka A, Lanier LL. Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection. J Exp Med 2005; 202:1477-82; PMID:16314433; http://dx.doi.org/10.1084/jem.20050240.
62. Dow SW, Fradkin LG, Liggitt DH, Willson AP, Heath TD, Potter TA. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol 1999; 163:1552-61; PMID:10415059.
63. Sottnik JL, Guth AM, Mitchell LA, Dow SW. Minimally invasive assessment of tumor angiogenesis by fine needle aspiration and flow cytometry. Angiogenesis 2010; 13:251-8; PMID:20734228; http://dx.doi.org/10.1007/s10456-010-9182-0.
64. Zaks K, Jordan M, Guth A, Sellins K, Kedl R, Izzo A, et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 2006; 176:7335-45; PMID:16751377.